All In Biotech

Drug Trial Radar · NCT05477797

Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.

Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma: a Prospective, Randomized, Controlled, Multicenter Clinical Study

Last checked: Nov 20, 2026Latest source record: Apr 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

420

Planned (sponsor's estimate)

Start

Feb 16, 2023

Primary completion

Jan 15, 2026

Study completion Jan 15, 2026

Sponsor

Lead sponsor
RenJi HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Newly Diagnosed Myeloma Patients, who achieved efficacy above VGPR (very good PR)after initial treatment were enrolled. Patients were then randomly assigned to Id and Rd groups for maintenance treatment. Therapeutic effectiveness will be reviewed monthly until intolerant side effect or disease progression appear . The follow-up period is approximately 2 years.

Conditions

  • Progression Free Survival
  • Overall Survival
  • Maintenance

Interventions

  • Ixazomib DX/Lenalidomide DXDrug

    After assessment of risk stratification,patients will be assigned to Id or Rd group randomly for maintenance therapy. Then they will be reviewed the efficacy monthly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the percentage of 2 year PFS(progression-free survival)Time frame: from randomization to the end of 2years maintenance.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • shanghai Jiaotong University School of Medicine, Renji Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.